Charles Schwab
ACER

Charles Schwab’s Acer Therapeutics Inc ACER Stock Holding History

Charles Schwab’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-11,934
Closed -$24K – 3374
2020
Q1 		$24K Hold
11,934
– – ﹤0.01% 3188
2019
Q4 		$48K Hold
11,934
– – ﹤0.01% 3124
2019
Q3 		$39K Hold
11,934
– – ﹤0.01% 3134
2019
Q2 		$47K Buy
+11,934
New +$227K ﹤0.01% 3153

Other funds holding ACER

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab's ACER Position: Q2 2020 in Review

Charles Schwab sold out of Acer Therapeutics Inc (ACER) in Q2 2020, closing a stake of 11,934 shares — an estimated $24K sold.

Charles Schwab first reported a position in ACER in Q2 2019 and held it in 4 quarters. The position peaked at $48K in Q4 2019. 34 funds tracked by Wall St. Rank hold ACER as of Q2 2020.

  • Charles Schwab reported no remaining Acer Therapeutics Inc position as of Q2 2020 after selling out during the quarter.
  • Charles Schwab sold 11,934 Acer Therapeutics Inc shares in Q2 2020, an estimated $24K.
  • Charles Schwab first reported a position in Acer Therapeutics Inc in Q2 2019 and held it in 4 quarters.
  • Charles Schwab's Acer Therapeutics Inc position peaked at $48K in Q4 2019.
  • 34 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q2 2020.

Based on Charles Schwab's 13F filing for Q2 2020, filed 14 Aug 2020.